Research Explorer

Your browser does not support JavaScript or JavaScript is not enabled. Without JavaScript some functions of this webapplication may be disabled or cause error messages. To enable JavaScript, please consult the manual of your browser or contact your system administrator.

Project

Use of the small GTPase Rab27b to diagnose and treat poor prognosis estrogen-receptor-positive (ER+) breast cancer

Outputs and Outcomes

Acronym

Rab27b-diagnostic

Code

F2015/IOF-CONCTT/006

Duration

15 April 2015 → 14 October 2016

Funding

Regional and community funding: Industrial Research Fund

Promotor

Olivier De Wever

Research disciplines

Medical and health sciences
- Morphological sciences
- Oncology
- Morphological sciences
- Oncology
- Morphological sciences
- Oncology

Keywords

Rab27b

Project description

Within this concepTT we want to convince a company to license our biomarker by validating the Rab27B score on a large patient group with 10 years clinical outcome data. This biomarker could be marketed as a unique prognostic biomarker to identify poor prognosis hormone-sensitive breast tumors that should receive adjuvant cytotoxic therapy

English

Dutch

English

Cookie settings

In addition to functional cookies which are necessary for the website to function, Ghent University uses non-functional cookies such as statistical cookies and social media cookies. These non-functional cookies can also be placed by third parties, for example to measure the use of the site or to share content on social media. Certain media are only available if you accept the cookies. You can set and modify your cookie preferences yourself. Find out what cookies we use and why in the Cookie Statement.

Analytics

AnalyticsWe'll collect information about your visit to our site. It helps us understand how the site is used – what's working, what might be broken and what we should improve.

Powered by